- Conditions
- Severe Asthma
- Interventions
- Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–15
of 15
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
- Interventions
- Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
- Other · Drug
- Lead sponsor
- DARTNet Institute
- Government
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Moderate to Severe Asthma
- Interventions
- Implementation bundle
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- St Louis, Missouri
- Conditions
- Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
- Interventions
- Budesonide-albuterol, Benralizumab
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Skokie, Illinois
- Conditions
- Asthma, Asthma Chronic, Asthma Severe Persistent With Exacerbation, Asthma Moderate Persistent With Exacerbation
- Interventions
- PARTICS using a single ICS add on, MART
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 3 more
- Conditions
- Asthma
- Interventions
- Albuterol eMDPI DS, albuterol
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more
- Conditions
- Asthma
- Interventions
- Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Asthma
- Interventions
- Dupilumab SAR231893 (REGN668)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
- Conditions
- Asthma, Asthma Attack, Asthma Exacerbations
- Interventions
- Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application
- Drug · Other
- Lead sponsor
- DARTNet Institute
- Government
- Eligibility
- 13 Years to 75 Years
- Enrollment
- 3,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Oral corticosteroid therapy (prednisone/prednisolone), Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more
- Conditions
- Asthma
- Interventions
- Dupilumab (SAR231893/REGN668), Asthma controller therapies (incl. prednisone/prednisolone), Asthma reliever therapies
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Rolling Hills Estates, California + 9 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,902 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more
- Conditions
- Asthma in Children
- Interventions
- Clinical decision support + education (CDS+) and population health management (PHM), Control
- Behavioral · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Asthma
- Interventions
- Dupilumab, placebo, ICS/LABA therapy, Salbutamol/albuterol, Levosalbutamol/levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 776 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 50
- States / cities
- Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more